Our data demonstrate that these molecules restore the DNA-binding activity in vitro, initiating the full reactivation of the p53 transcriptional program and leading to in vivo tumor growth inhibition (TGI) in xenograft and syngeneic mouse tumor models. This evidence concerns the gene TP53 and neoplasm.